Cosentyx 150 mg solution for injection in pre-filled syringe
Sponsors
Tartu University Hospital, Universitaetsklinikum Erlangen AöR, Celltrion Inc., IRCCS Istituto Giannina Gaslini
Conditions
Chronic rhinosinusitis with nasal polypsJuvenile idiopathic arthritisPlaque psoriasisPsoriatic arthritis
Phase 3
A prospective, randomized, controlled, open label, assessor-blinded, parallel-group Phase III clinical trial to evaluate the impact of tapering systemic immunosuppressive therapy in a treat-to-target approach on maintaining minimal disease activity in adult subjects with psoriatic arthritis
RecruitingCTIS2023-508251-39-00
Start: 2020-09-18Target: 370Updated: 2026-01-20
A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Efficacy and Safety of CT-P55 with Cosentyx in Patients with Moderate to Severe Plaque Psoriasis
Active, not recruitingCTIS2024-513348-27-00
Start: 2025-05-09Target: 375Updated: 2025-07-01
Phase 4
Treatment of non-type 2 CRSwNP with anti-IL-17 antibody (secukinumab)
CompletedCTIS2023-505711-20-00
Start: 2023-08-13End: 2024-01-23Target: 4Updated: 2023-08-11
Toward personalized medicine to guide drug withdrawal in children with juvenile idiopathic arthritis in clinical remission: a randomized clinical trial comparing early versus late drug withdrawal combining imaging and multi-Omics.
RecruitingCTIS2024-514732-24-00
Start: 2025-04-28Target: 328Updated: 2025-08-26